Sosei Says `Rapidly' Renewing Pipeline After Allergan Deal

  • CEO-Elect Peter Bains says "a lot more to come" for company
  • Tokyo-based biopharmaceutical firm could make bolt-on deals

Sosei Group is "rapidly" replenishing its portfolio after announcing a $125 million drug development agreement with Allergan Plc last week, the Japanese pharmaceutical company’s incoming chief executive officer said.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.